{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:11:22Z","timestamp":1779315082246,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11845-022-03093-9","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T15:04:09Z","timestamp":1657724649000},"page":"1041-1049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of neoadjuvant pyrotinib plus docetaxel\/liposomal doxorubicin\/cyclophosphamide for HER2-positive breast cancer"],"prefix":"10.1007","volume":"192","author":[{"given":"Chunyu","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hancheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengze","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"issue":"2","key":"3093_CR1","first-page":"171","volume":"104","author":"KP Trayes","year":"2021","unstructured":"Trayes KP, Cokenakes SEH (2021) Breast cancer treatment. Am Fam Physician 104(2):171\u2013178","journal-title":"Am Fam Physician"},{"issue":"1","key":"3093_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3093_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"3093_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/OP.21.00172","volume":"17","author":"O Martinez-Saez","year":"2021","unstructured":"Martinez-Saez O, Prat A (2021) Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract 17(10):594\u2013604. https:\/\/doi.org\/10.1200\/OP.21.00172","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"3093_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10549-022-06575-7","volume":"193","author":"S Pernas","year":"2022","unstructured":"Pernas S, Tolaney SM (2022) Clinical trial data and emerging strategies: HER2-positive breast cancer. Breast Cancer Res Treat 193(2):281\u2013291. https:\/\/doi.org\/10.1007\/s10549-022-06575-7","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 6","key":"3093_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ajco.13655","volume":"17","author":"J Chen","year":"2021","unstructured":"Chen J, Colosimo M, Lim E (2021) The management of HER2-positive early breast cancer: current and future therapies. Asia Pac J Clin Oncol 17(Suppl 6):3\u201312. https:\/\/doi.org\/10.1111\/ajco.13655","journal-title":"Asia Pac J Clin Oncol"},{"key":"3093_CR7","doi-asserted-by":"publisher","unstructured":"Gradishar WJ, Anderson BO, Abraham J et al (2020) Breast cancer, version 3.2020, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw 18 (4):452\u2013478. https:\/\/doi.org\/10.6004\/jnccn.2020.0016","DOI":"10.6004\/jnccn.2020.0016"},{"issue":"3","key":"3093_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10549-013-2790-9","volume":"142","author":"X Chen","year":"2013","unstructured":"Chen X, Ye G, Zhang C et al (2013) Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer. Breast Cancer Res Treat 142(3):549\u2013558\u00a0https:\/\/doi.org\/10.1007\/s10549-013-2790-9, https:\/\/doi.org\/10.1007\/s10549-013-2761-1","journal-title":"Breast Cancer Res Treat"},{"key":"3093_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.breast.2022.03.015","volume":"63","author":"S Zheng","year":"2022","unstructured":"Zheng S, Li L, Chen M et al (2022) Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: a retrospective cohort study at FUSCC. Breast 63:177\u2013186. https:\/\/doi.org\/10.1016\/j.breast.2022.03.015","journal-title":"Breast"},{"issue":"11","key":"3093_CR10","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.cjco.2021.06.019","volume":"3","author":"MM Alhussein","year":"2021","unstructured":"Alhussein MM, Mokbel A, Cosman T et al (2021) Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis. CJC Open 3(11):1372\u20131382. https:\/\/doi.org\/10.1016\/j.cjco.2021.06.019","journal-title":"CJC Open"},{"issue":"4","key":"3093_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccl.2019.07.005","volume":"37","author":"R Barish","year":"2019","unstructured":"Barish R, Gates E, Barac A (2019) Trastuzumab-induced cardiomyopathy. Cardiol Clin 37(4):407\u2013418. https:\/\/doi.org\/10.1016\/j.ccl.2019.07.005","journal-title":"Cardiol Clin"},{"issue":"3","key":"3093_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10557-021-07181-3","volume":"36","author":"Q Wu","year":"2022","unstructured":"Wu Q, Bai B, Tian C et al (2022) The molecular mechanisms of cardiotoxicity induced by HER2, VEGF, and tyrosine kinase inhibitors: an updated review. Cardiovasc Drugs Ther 36(3):511\u2013524. https:\/\/doi.org\/10.1007\/s10557-021-07181-3","journal-title":"Cardiovasc Drugs Ther"},{"key":"3093_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejps.2017.01.021","volume":"110","author":"X Li","year":"2017","unstructured":"Li X, Yang C, Wan H et al (2017) Discovery and development of pyrotinib: a novel irreversible EGFR\/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci 110:51\u201361. https:\/\/doi.org\/10.1016\/j.ejps.2017.01.021","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"3093_CR14","first-page":"10863","volume":"13","author":"H Yang","year":"2021","unstructured":"Yang H, Wang W (2021) Comparison of pyrotinib or lapatinib with chemotherapy for patients with HER2 positive breast cancer after first-line treatment failure: a retrospective study. Am J Transl Res 13(9):10863\u201310870","journal-title":"Am J Transl Res"},{"key":"3093_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.608781","volume":"11","author":"H Liao","year":"2021","unstructured":"Liao H, Huang W, Liu Y et al (2021) Efficacy and safety of pyrotinib versus T-DM1 in HER2+ metastatic breast cancer patients pre-treated with trastuzumab and a taxane: a bayesian network meta-analysis. Front Oncol 11:608781. https:\/\/doi.org\/10.3389\/fonc.2021.608781","journal-title":"Front Oncol"},{"key":"3093_CR16","doi-asserted-by":"publisher","unstructured":"Li F, Xu F, Li J et al (2021) Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study. Ann Transl Med 9(2):103. https:\/\/doi.org\/10.21037\/atm-20-4054","DOI":"10.21037\/atm-20-4054"},{"key":"3093_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.855512","volume":"12","author":"X Mao","year":"2022","unstructured":"Mao X, Lv P, Gong Y et al (2022) Pyrotinib-containing neoadjuvant therapy in patients with HER2-positive breast cancer: a multicenter retrospective analysis. Front Oncol 12:855512. https:\/\/doi.org\/10.3389\/fonc.2022.855512","journal-title":"Front Oncol"},{"key":"3093_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Litiere S et al (2016) RECIST 1.1 - standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur J Cancer 62:138\u2013145. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.082","journal-title":"Eur J Cancer"},{"issue":"5","key":"3093_CR19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/s0960-9776(03)00106-1","volume":"12","author":"KN Ogston","year":"2003","unstructured":"Ogston KN, Miller ID, Payne S et al (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12(5):320\u2013327. https:\/\/doi.org\/10.1016\/s0960-9776(03)00106-1","journal-title":"Breast"},{"issue":"12","key":"3093_CR20","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A et al (2020) Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res 26(12):2838\u20132848. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3492","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3093_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.clbc.2014.11.004","volume":"15","author":"MF Rimawi","year":"2015","unstructured":"Rimawi MF, Aleixo SB, Rozas AA et al (2015) A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. Clin Breast Cancer 15(2):101\u2013109. https:\/\/doi.org\/10.1016\/j.clbc.2014.11.004","journal-title":"Clin Breast Cancer"},{"key":"3093_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2017.08.020","volume":"85","author":"S Loibl","year":"2017","unstructured":"Loibl S, de la Pena L, Nekljudova V et al (2017) Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). Eur J Cancer 85:133\u2013145. https:\/\/doi.org\/10.1016\/j.ejca.2017.08.020","journal-title":"Eur J Cancer"},{"key":"3093_CR23","doi-asserted-by":"publisher","unstructured":"Holloway RW, Marignani PA (2021) Targeting mTOR and glycolysis in HER2-positive breast cancer. Cancers (Basel) 13(12). https:\/\/doi.org\/10.3390\/cancers13122922","DOI":"10.3390\/cancers13122922"},{"key":"3093_CR24","doi-asserted-by":"publisher","unstructured":"Lee J, Liu H, Pearson T et al (2021) PI3K and MAPK Pathways as targets for combination with the Pan-HER irreversible inhibitor neratinib in HER2-positive breast cancer and TNBC by kinome RNAi screening. Biomedicines 9(7). https:\/\/doi.org\/10.3390\/biomedicines9070740","DOI":"10.3390\/biomedicines9070740"},{"issue":"10","key":"3093_CR25","first-page":"2103","volume":"9","author":"JC Xuhong","year":"2019","unstructured":"Xuhong JC, Qi XW, Zhang Y, Jiang J (2019) Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res 9(10):2103\u20132119","journal-title":"Am J Cancer Res"},{"key":"3093_CR26","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.2147\/OTT.S194768","volume":"12","author":"Z Gao","year":"2019","unstructured":"Gao Z, Song C, Li G et al (2019) Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib. Onco Targets Ther 12:2777\u20132787. https:\/\/doi.org\/10.2147\/OTT.S194768","journal-title":"Onco Targets Ther"},{"issue":"1","key":"3093_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(11)70336-9","journal-title":"Lancet Oncol"},{"key":"3093_CR28","doi-asserted-by":"publisher","unstructured":"Sheikh F, Nazir A, Yasmeen S et al (2019) Pathologic complete response in HER2-positive breast cancer patients receiving trastuzumab in neoadjuvant setting. J Coll Physicians Surg Pak 29(2):159\u2013163. https:\/\/doi.org\/10.29271\/jcpsp.2019.02.159","DOI":"10.29271\/jcpsp.2019.02.159"},{"issue":"16","key":"3093_CR29","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s40265-018-0997-0","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair HA (2018) Pyrotinib: first global approval. Drugs 78(16):1751\u20131755. https:\/\/doi.org\/10.1007\/s40265-018-0997-0","journal-title":"Drugs"},{"issue":"5","key":"3093_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3727\/096504020X15960154585410","volume":"28","author":"J Yi","year":"2020","unstructured":"Yi J, Chen S, Yi P et al (2020) Pyrotinib sensitizes 5-fluorouracil-resistant HER2(+) breast cancer cells to 5-fluorouracil. Oncol Res 28(5):519\u2013531. https:\/\/doi.org\/10.3727\/096504020X15960154585410","journal-title":"Oncol Res"},{"key":"3093_CR31","doi-asserted-by":"publisher","unstructured":"Yao DS, Wang W, Chang JY et al (2021) Neoadjuvant pyrotinib plus nab-paclitaxel, doxorubicin, and cyclophosphamide for HER2-positive locally advanced breast cancer: a retrospective case-series study. Gland Surg 10(12):3362\u20133368. https:\/\/doi.org\/10.21037\/gs-21-770","DOI":"10.21037\/gs-21-770"},{"key":"3093_CR32","doi-asserted-by":"publisher","unstructured":"Li Q, Wang Y, Zhu M, Gu Y, Tang Y (2021) Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study. Gland Surg 10(12):3389\u20133402. https:\/\/doi.org\/10.21037\/gs-21-794","DOI":"10.21037\/gs-21-794"},{"key":"3093_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ejca.2022.01.022","volume":"165","author":"Z Liu","year":"2022","unstructured":"Liu Z, Wang C, Chen X et al (2022) Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial. Eur J Cancer 165:157\u2013168. https:\/\/doi.org\/10.1016\/j.ejca.2022.01.022","journal-title":"Eur J Cancer"},{"issue":"3","key":"3093_CR34","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1158\/1078-0432.CCR-21-2936","volume":"28","author":"Z Song","year":"2022","unstructured":"Song Z, Lv D, Chen SQ et al (2022) Pyrotinib in patients with HER2-amplified advanced non-small cell lung cancer: a prospective, multicenter, single-arm trial. Clin Cancer Res 28(3):461\u2013467. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2936","journal-title":"Clin Cancer Res"},{"key":"3093_CR35","doi-asserted-by":"publisher","unstructured":"Zheng YF, Fu X, Wang XX et al (2021) Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients. World J Clin Cases 9(33):10075\u201310087. https:\/\/doi.org\/10.12998\/wjcc.v9.i33.10075","DOI":"10.12998\/wjcc.v9.i33.10075"},{"issue":"2","key":"3093_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-021-04371-6","volume":"89","author":"XZ Wen","year":"2022","unstructured":"Wen XZ, Pan QZ, Xu BS et al (2022) Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma. Cancer Chemother Pharmacol 89(2):209\u2013215. https:\/\/doi.org\/10.1007\/s00280-021-04371-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3093_CR37","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/j.clbc.2021.05.008","volume":"22","author":"X He","year":"2022","unstructured":"He X, Dai X, Ji J et al (2022) Nine-year median follow-up of cardiotoxicity and efficacy of trastuzumab concurrently with anthracycline-based and anthracycline-free neoadjuvant chemotherapy in HER2-positive breast cancer patients. Clin Breast Cancer 22(1):e80\u2013e90. https:\/\/doi.org\/10.1016\/j.clbc.2021.05.008","journal-title":"Clin Breast Cancer"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03093-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-022-03093-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03093-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T07:12:21Z","timestamp":1686208341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-022-03093-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["3093"],"URL":"https:\/\/doi.org\/10.1007\/s11845-022-03093-9","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was permitted by Ethics Committee of Affiliated Hospital of Chengde Medical University with approval of 21\u20130924.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}